Why the study?
Does SCH 58235 reduce serum total cholesterol and liver cholesteryl esters in a cholesterol-fed hamster model?
Population
7-day cholesterol-fed hamster model
Comparison
SCH 58235 (1---[3---hydroxypropyl]---2-azetidinon… vs Control
Design
Preclinical
Follow-up
7 days
Authors
Loading...
Supports advancement of SCH 58235 to clinical testing; leaves open human efficacy and safety.
Does SCH 58235 reduce serum total cholesterol and liver cholesteryl esters in a cholesterol-fed hamster model?
SCH 58235 is a highly potent, rationally designed inhibitor of cholesterol absorption that significantly reduces liver cholesteryl esters in a preclinical model.
Rosenblum et al. (1998) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: